暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
自选模拟交易
美股期权个股详情
CRVS241220C8000
- 2.23
- -0.59-20.92%
延时15分钟行情收盘价 11/26 15:59 (美东)
2.23最高价2.23最低价
2.23今开2.82昨收2张成交量468张未平仓合约数8.00行权价446.00成交额221.31%隐含波动率17.18%溢价2024/12/20到期日0.73内在价值100合约乘数23天距到期日1.50时间价值100合约规模美式期权类型0.6706Delta0.0737Gamma3.88杠杆倍数-0.0385Theta0.0023Rho2.60有效杠杆0.0080Vega
分时
- 5日
- 日K
新闻
根据Corvus保险网络威胁报告，攻击者针对VPN的勒索软件事件占第三季度的28.7%。
2024年第三季度的 ransomware 活动主要由包括 RansomHub、PLAY 和 LockBit 3.0 在内的成熟团体主导。 波士顿，2024年11月20日 / 美通社 / -- Corvus Insurance 是 The 的全资子公司
“减肥双雄”领衔医药股大跌，特朗普的新卫生部长反对疫苗和减肥药
在corvus pharmaceuticals的内部买家坐拥390万美元的利润
在过去12个月内购买了科尔瓦制药公司（纳斯达克：CRVS）股票的内部人士不太可能受到该股票在过去一周13%下跌的严重影响。即使在此之后
美疫苗股集体下挫！特朗普竟任命反疫苗人士担任美国卫生部长
corvus pharmaceuticals在2024年ACR Convergence会议上发布了支持Soquelitinib在系统性硬化症中有效性的最新临床前数据。
corvus pharmaceuticals在ACR Convergence 2024上发布了soquelitinib在免疫性疾病中的有效性的新的临床前数据。Quiver 人工智能 摘要corvus pharmaceuticals宣布了临床前数据。
corvus pharmaceuticals 发布新一期临床前数据，突出显示Soquelitinib治疗系统性硬化症的潜力
有助于支持ITk抑制作为治疗广泛区间免疫疾病的新型治疗方法的证据不断增加。数据将在ACR Convergence 2024的海报上展示。
评论
$Corvus Pharmaceuticals (CRVS.US)$
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Corvus Pharmaceuticals announced new preclinical data showing that soquelitinib, their lead ITK inhibitor, could potentially prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. The study used Fra-2 transgenic mice, which mirror human systemic sclerosis features. After seven weeks of oral soquelitinib...
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Corvus Pharmaceuticals announced new preclinical data showing that soquelitinib, their lead ITK inhibitor, could potentially prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. The study used Fra-2 transgenic mice, which mirror human systemic sclerosis features. After seven weeks of oral soquelitinib...
1
$Corvus Pharmaceuticals (CRVS.US)$
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Corvus Pharmaceuticals (NASDAQ: CRVS) presented new data at SITC's 39th Annual Meeting showing ciforadenant's potential to overcome resistance to anti-PD1 immunotherapy in metastatic castration resistant prostate cancer (mCRPC). The research, selected as a Top 100 abstract, identified SPP...
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Corvus Pharmaceuticals (NASDAQ: CRVS) presented new data at SITC's 39th Annual Meeting showing ciforadenant's potential to overcome resistance to anti-PD1 immunotherapy in metastatic castration resistant prostate cancer (mCRPC). The research, selected as a Top 100 abstract, identified SPP...
2
$Corvus Pharmaceuticals (CRVS.US)$ Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
3 HOURS AGO, 1:40 PM EST
VIA GLOBENEWSWIRE
BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company'...
3 HOURS AGO, 1:40 PM EST
VIA GLOBENEWSWIRE
BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company'...
5
$Corvus Pharmaceuticals (CRVS.US)$vibrating so much every day… what’s the reasonable price???
阅读更多